Drug lookup | Fillwise

MOCLOBEMIDE

5 general benefit · 1 not a benefit

Other products in the same Health Canada class (N06A) — coverage varies; not interchangeable

Amitriptyline (Elavil): general benefit
Citalopram (Celexa): general benefit, Not a benefit
Clomipramine (Anafranil Tab): general benefit
Desipramine (Pertofrane): general benefit, Not a benefit
Doxepin (Sinequan): general benefit, Not a benefit
Duloxetine (Cymbalta): general benefit, Not a benefit

17 more in the class list below

Moclobemide · DIN 02232148 · 100mg · tablet

General benefitMarketed · checked 2026-09-19

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Moclobemide · DIN 02232148 Manufacturer: A A Pharma Inc.; listing date 1998-12-31 Health Canada: Marketed since 2018-03-27 · brand MOCLOBEMIDE · ATC N06AG02 MOCLOBEMIDE · form Tablet · route Oral · ingredients MOCLOBEMIDE 100 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Moclobemide: Formulary list price $0.3400/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51594 · Verify on the e-Formulary ↗ (DIN 02232148)

Source record

DIN 02232148: Moclobemide Raw flags: sec3=Y Item: 281604066; group id 465; item number 1170; lccId None; manufacturer id AAP Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.3400; ministry $0.3400 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02232148 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51594

Interchangeable products

Manerix · DIN 00899348 · not recorded

Shortage status: resolved shortage (ended 2023-07-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02232148

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Moclobemide · DIN 02232150 · 150mg · tablet

General benefitMarketed · checked 2026-09-19

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Moclobemide · DIN 02232150 Manufacturer: A A Pharma Inc.; listing date 1998-12-31 Health Canada: Marketed since 2018-05-24 · brand MOCLOBEMIDE · ATC N06AG02 MOCLOBEMIDE · form Tablet · route Oral · ingredients MOCLOBEMIDE 150 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Moclobemide: Formulary list price $0.5295/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5295 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02232150: Moclobemide Raw flags: sec3=Y Item: 281604067; group id 465; item number 1171; lccId None; manufacturer id AAP Source form: Tab; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.5295; ministry $0.5295 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02232150 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51595

Interchangeable products

Manerix · DIN 00899356 · $0.5295

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02232150

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Manerix · DIN 02166747 · 300mg · tablet

General benefitMarketed · checked 2026-09-19

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Manerix · DIN 02166747 Manufacturer: Meda AB; listing date 1997-04-10 Health Canada: Marketed since 2021-06-24 · brand MANERIX · ATC N06AG02 MOCLOBEMIDE · form Tablet · route Oral · ingredients MOCLOBEMIDE 300 MG · company Bausch health, canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $1.0399 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18969 · Verify on the e-Formulary ↗ (DIN 02166747)

Source record

DIN 02166747: Manerix Raw flags: sec3=Y Item: 281604084; group id 465; item number 1172; lccId None; manufacturer id MAB Source form: Tab; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $1.7921; ministry $1.0399 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02166747 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18969

Interchangeable products

Moclobemide · DIN 02240456 · $1.0399

Shortage status: discontinued (2025-01-07, reported by BAUSCH HEALTH, CANADA INC.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02166747

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Moclobemide · DIN 02240456 · 300mg · tablet

General benefitMarketed · checked 2026-09-19

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Moclobemide · DIN 02240456 Manufacturer: A A Pharma Inc.; listing date 2000-01-17 Health Canada: Marketed since 2017-11-14 · brand MOCLOBEMIDE · ATC N06AG02 MOCLOBEMIDE · form Tablet · route Oral · ingredients MOCLOBEMIDE 300 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Moclobemide: Formulary list price $1.0399/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.0399 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64019 · Verify on the e-Formulary ↗ (DIN 02240456)

Source record

DIN 02240456: Moclobemide Raw flags: sec3=Y Item: 281604084; group id 465; item number 1172; lccId None; manufacturer id AAP Source form: Tab; strength: 300mg Recorded listing: General benefit Source prices (unrounded): $1.0399; ministry $1.0399 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240456 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64019

Interchangeable products

Manerix · DIN 02166747 · $1.0399

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Manerix · DIN 00899356 · 150mg · tablet

General benefitDormant since 2026-07-31 · checked 2026-09-19 · What does dormant mean?

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Manerix · DIN 00899356 Manufacturer: Meda AB; listing date 1996-10-01 Health Canada: Dormant since 2026-07-31 · brand MANERIX · ATC N06AG02 MOCLOBEMIDE · form Tablet · route Oral · ingredients MOCLOBEMIDE 150 MG · company Bausch health, canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.5295 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13256 · Verify on the e-Formulary ↗ (DIN 00899356)

Source record

DIN 00899356: Manerix Raw flags: sec3=Y Item: 281604067; group id 465; item number 1171; lccId None; manufacturer id MAB Source form: Tab; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.9126; ministry $0.5295 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00899356 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13256

Interchangeable products

Moclobemide · DIN 02232150 · $0.5295

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2026-07-31 — choose a marketed DIN from the same-category list.

Manerix · DIN 00899348 · 100mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1997-12-04 — choose a marketed DIN from the same-category list.Discontinued 1997-12-04 · checked 2026-09-19

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1997-12-04 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1997-12-04 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Manerix · DIN 00899348 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 1997-12-04 · brand MANERIX TAB 100MG · ATC N06AG02 MOCLOBEMIDE · form Tablet · route Oral · ingredients MOCLOBEMIDE 100 MG/TAB · company Hoffmann-la roche limited · schedule Prescription

Check this DIN again · Health Canada product record

Manerix: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13096 · Verify on the e-Formulary ↗ (DIN 00899348)

Source record

DIN 00899348: Manerix Raw flags: notABenefit=Y, sec3=Y Item: 281604066; group id 465; item number 1170; lccId None; manufacturer id HLR Source form: Tab; strength: 100mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00899348 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13096

Interchangeable products

Moclobemide · DIN 02232148 · $0.3400

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 1997-12-04 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

ESCITALOPRAM

· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab

FLUOXETINE HCL

· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol

FLUVOXAMINE MALEATE

· 6 products · General benefit · strengths: 50mg, 100mg · Tab

IMIPRAMINE

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab

NORTRIPTYLINE

· 2 products · General benefit · strengths: 10mg, 25mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more

Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS MANERIX (moclobemide) is indicated for the treatment of major depressive disorder (MDD) in adults. 1.1 Pediatrics  The safety and efficacy of MANERIX has not been studied in pediatric population (<18 years of age). Therefore, its use is not indicated in this population. 1.2 Geriatrics  No dosage adjustments are necessary in elderly patients (see 10 CLINICAL PHARMACOLOGY, Special Populations, Single and Multiple Dose). https://pdf.hres.ca/dpd_pm/00061932.PDF PM date: June 23, 2021 Source product: MANERIX; DIN 02166747; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Manerix · DIN 02166747 Shortage status: discontinued (2025-01-07, reported by BAUSCH HEALTH, CANADA INC.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02166747

Check this DIN again

Manerix · DIN 00899356 Shortage status: discontinued (2025-01-07, reported by BAUSCH HEALTH, CANADA INC.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00899356

Check this DIN again

Health Canada: dormant products

Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Manerix: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026